Burosumab
IRB 11746
Phase 1 small_molecule active
Quick answer
Burosumab for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) is a Phase 1 program (small_molecule) at Ultragenyx UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx UK Limited
- Indication
- Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active